Before Dropbox and Google Drive, there was Carbonite and Mozy.
Both of those pioneer firms launched in 2005, and were among the early players in online data backup services. They enabled people to pay a few bucks a month for... Read more »
A Seattle-based company developing a universal source of stem cells for cell therapies has been acquired by Tokyo-based Astellas Pharma for $102.5 million.
Universal Cells’ technology aims to make stem cells that don’t have some of the problems that current cell... Read more »
In order to better position itself against competitors like Costco Wholesale (NASDAQ: COST) and Amazon (NASDAQ: AMZN), Sam’s Club, the bulk retailer owned by Walmart (NYSE: WMT), is now offering free shipping for many items as part of... Read more »
[Updated, 2/16/18, 9:10 a.m. See below.] Using software to speed up drug discovery isn’t a new idea, but it’s generating more interest thanks to artificial intelligence. BioXcel Therapeutics is trying to parlay that momentum into an initial public stock... Read more »
Critical communications software company Everbridge has made a $33.6 million cash bid to acquire Norwegian competitor Unified Messaging Systems (UMS) in a deal that would grow its overseas presence.
Burlington, MA-based Everbridge (NASDAQ: EVBG) said its purchase offer represents a... Read more »
As the last year has shown, the tech industry has a significant problem with sexual harassment and ensuring that women are treated equitably in the workplace.
Now, some founders are seeking to use tech tools such as chatbots, artificial intelligence, analytics,... Read more »
Experts across the robotics and artificial intelligence industries are coming together for our fourth annual Robo Madness event. It all takes place on April 12 at iRobot in Bedford, MA.
Join us for interactive talks, panels, and demos from an elite... Read more »
Tetraphase Pharmaceuticals’ ups and downs have continued, as new data have clouded the future of the Watertown, MA, company’s experimental antibiotic, eravacycline, once again.
Tetraphase (NASDAQ: TTPH) reported that eravacycline failed a 1,200-patient Phase 3 study called Ignite3, one... Read more »